October 04, 2016

Join John Thompson, PhD, Chief Technology Officer at Claritas Genomics; Natalie Vena, Genetic Counselor at Claritas Genomics; and David Miller, MD, PhD, Medical Director at Claritas Genomics and Clinical Geneticist at Boston Children's Hospital as they discuss the technology of whole exome testing, the algorithms used by clinicians when considering whether to order genetic testing, and case studies showing the utility of whole exome sequencing.

This webinar, recording June 28, 2016 is available...

September 22, 2016

Advances in Genome Biology and Technology (AGBT) 2016 is holding a Precision Medicine conference in Scottsdale, Arizona, September 22-24. As per the AGBT website, "This new meeting will bring together leading genomics researchers, healthcare professionals, and healthcare industry stakeholders to rigorously explore exciting developments at the interface of genomics, medicine, and health." Claritas's Chief Technology Officer, Dr. John Thompson, is attending and will present a poster entitled, "Improved sensitivity for...

August 22, 2016

Claritas Genomics has launched the Bone Marrow Failure Region of Interest test, an exome-based test that assesses 86 genes related to known causes of hereditary bone marrow failure. Developed in collaboration with experts in hematology at Boston Children's Hospital, this assay's first results are issued at 4 weeks, providing critical information to providers and patients for treatment and management decisions. ...

August 22, 2016

The Primary Immunodeficiency Region of Interest is designed to facilitate rapid genetic diagnosis of patients with hereditary Primary Immunodeficiency. Such patients may have a disease that would benefit from immediate treatment and customized clinical management. Developed in collaboration with experts in the Division of Immunology at Boston Children’s Hospital, this Region of Interest evaluates 283 genes related to the known causes of Primary Immunodeficiency within a rapid turnaround...

August 15, 2016

Claritas Genomics announces two new phenotypes to our Pediatric Neurology Region of Interest test as well as updates to pre-existing gene lists.

  • The Autism gene list includes 196 genes specifically curated to autism.
  • The Developmental Delay/Intellectual Disability gene list includes 340 genes relevant to DD/ID.

These two new sub-phenotypes offer providers more powerful testing for their patients with complex pediatric neurology phenotypes. In addition,...

August 05, 2016

Claritas Genomics has launched the Nephrotic Syndrome Region of Interest (NS-ROI). The NS-ROI sequences 42 genes relevant to Nephrotic Syndrome, an increase of 13 genes from the original Nephrotic Syndrome Panel, which is now discontinued. 

The NS-ROI is built on the Claritas Clinical Exome platform, which allows expansion into any Claritas exome product, and allows rapid changes to the gene list as discoveries in the field occur.  Additionally, clients can request raw data in the form of VCF and BAM files for further investigation into the patient's exome. Gene...

April 19, 2016

Boston, Massachusetts │ April 19, 2016 – Claritas Genomics today announced the publication of a study demonstrating the superior sensitivity and speed of its proprietary orthogonal sequencing process compared to industry standard practice.  The study, ‘Orthogonal Next Generation Sequencing (NGS) for High Throughput Clinical Diagnostics’  was published today in the online edition of Scientific Reports.  Orthogonal sequencing is the practice of running two gene sequencing technologies in parallel to assist...

April 04, 2016

Marcia Nizzari, MS, CIO will speak at Bio*IT World Conference & Expo 2016 at the Seaport World Trade Center April 5-7. Ms. Nizzari's talk is Thursday, April 7 at 2:30pm and is entitled "A Clinical Genetics Diagnostic System Incorporating Next-Gen Sequencing and Informatics to Advance Pediatric Genetics Care."

The following is the summary of her talk which is included in the Track brochure: 
Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers...

February 17, 2016

Our scientists will be available during the following times to discuss their posters. If you miss these times, visit us at booth 419.

THURSDAY, MARCH 10, 10:30a-12:00p

291- John Thompson, PhD: Two exomes are better than one; Orthogonal NGS for Clinical Diagnostics
Whole exome/genome sequencing studies have revolutionized the diagnosis of genetic disorders. However, typical high-throughput sequencing strategies require Sanger confirmation to meet the exacting demands of clinical diagnostic sequencing. To address this gap, we tested orthogonal next-...

January 21, 2016

CAMBRIDGE, Massachusetts; January 21, 2016 – 2015 was a year of advances for Claritas Genomics continuing the company’s mission to advance precision care for children. The company secured $15 million for its Series B, launched new diagnostic gene tests, announced a partnership with the world’s largest rare disease patient advocacy organization, sequenced 19,600 research exomes, announced its Scientific Advisory Board and became one of only eight clinical laboratories in the US to be awarded the International Standardization Organization’s (ISO) 15189 accreditation by the American...

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.